Research
Hormonal
Reducing dietary glycemic index and load may have favorable effects on serum lipids, but evidence for weight maintenance and disease prevention is inconclusive.
Reducing glycemic index/load may help serum lipids, but do not rely on it for weight loss or disease prevention as evidence is inconclusive.
ModerateQualifiesMEDIUM confidence
Although there is some experimental evidence that a reduction of the dietary glycaemic index and glycaemic load may have favourable effects on some metabolic risk factors such as serum lipids, the evidence for a role in weight maintenance and prevention of diet-related diseases is inconclusive.
Why this rating
Evidence is described as 'some experimental' for lipids and 'inconclusive' for other outcomes.
Source
Scientific Opinion on Dietary Reference Values for carbohydrates and dietary fibre
EFSA Panel on Dietetic Products et al. · EFSA Journal · 2010
DOI 10.2903/j.efsa.2010.1462
clinical_guidelineCited 883×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- A carbohydrate intake of 45-60% of total energy (E%) is sufficient to meet metabolic needs and prevent ketosis in adults and children over one year, provided fat and protein intakes are balanced.Good
- A dietary fiber intake of 25 g/day is adequate for normal laxation in adults, with potential health benefits at higher intakes.Good
- There is insufficient evidence to set an upper limit for added sugar intake based on health risks such as dental caries, weight gain, or metabolic effects.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →